Inventiva (ADR)
Developing lanifibranor, an oral MASH candidate, through a pivotal global trial.
Something off on this page? Send us feedback.
Profile
Develops lanifibranor, an oral MASH candidate, and earns near-term revenue from licensing milestones rather than product sales. Its only active program is in a pivotal trial, while regional partners control rights in parts of Asia.
Develops lanifibranor, a once-daily oral small molecule designed for adults with metabolic dysfunction-associated steatohepatitis. The compound is its only active clinical candidate and anchors a global pivotal trial; no products are approved for sale and it has never generated product-sales revenue.
Operates from Daix, France, retaining global control of the pivotal trial while CTTQ holds rights in Greater China and Hepalys controls development and commercialization in Japan and South Korea. A regulatory filing and commercial launch remain conditional on favorable trial outcomes, regulatory acceptance and financing; future economics also depend on partner execution.
Company facts
Key statistics
Year to date −1.2% · Average volume (30d) 705.4K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 17, 2026 | Cantor Fitzgerald | Initiate | Overweight | ||
| Jan 28, 2026 | H.C. Wainwright | Target | $20 | $24 | |
| Jan 27, 2026 | Barclays | Target | $18 | ||
| Jan 12, 2026 | Leerink Partners | Target | $12 | ||
| Jan 7, 2026 | UBS | Target | $12 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Mar 30, 2026Q4 FY25 | −$0.23 | −$1.07 | −365.2% | $5.2M | $2.3M | −55.3% | +1.28% |
| Sep 25, 2025Q2 FY25 | −$0.41 | −$1.89 | −361.7% | $8.7M | $5.2M | −39.8% | +0.67% |
| May 23, 2025 | −$0.47 | −$2.69 | −472.9% | $6.4M | $6.7M | +4.6% | +8.74% |
| Sep 25, 2024Q2 FY24 | −$0.56 | −$1.01 | −81.1% | — | $2.9M | — | −17.51% |
Financial highlights
| 12 quarters | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.7M | $19.2M | $3.2M | $7.5M | $5.2M | $33.4K | |
| Gross profit | $7.1M | $18.5M | $2.6M | $8.1M | $3.2M | −$1.4M | |
| Operating income | −$63.7M | −$55.3M | −$60.5M | −$52.5M | −$65.8M | −$85.9M | |
| Net income | −$64.0M | −$63.9M | −$56.8M | −$156.6M | −$203.8M | −$205.0M | |
| Diluted EPS | −$1.52 | −$1.31 | −$1.09 | −$3.01 | −$1.88 | −$0.32 | |
| Gross margin | 93.1% | 96.6% | 80.8% | 108.1% | 61.7% | -4,062.1% | |
| Operating margin | -830.6% | -288.4% | -1,911.1% | -700.9% | -1,275.3% | -257,582.5% |
Revenue by geography · FY25
Balance sheet, Dec 31, 2025Cash & short-term investments $115.0M · Total debt $68.8M · Total assets $288.4M · Shareholders' equity −$33.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 51.98M · Float 43.97M · 84.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Invus Public Equities, L.P. | 14.81M | 10.60% | 13G | Jul 31, 2025 |
| Sofinnova Crossover I SLP | 12.33M | 5.60% | 13G | Feb 17, 2026 |
| Yiheng Capital Partners, L.P. | 7.60M | 5.46% | 13G | Nov 13, 2025 |
| Samsara Biocapital, LLC | 5.19M | 9.99% | 13F | May 15, 2026 |
| Caligan Partners LP | 4.97M | 9.57% | 13F | May 15, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
- Madrigal Pharmaceuticals
Approved oral MASH therapy for the same F2–F3 patient pool.
- Novo Nordisk (ADR)
Approved GLP-1 therapy competing for F2–F3 MASH patients.
- GSK (ADR)
Phase 3 FGF21 therapy targeting the same F2–F3 MASH patients.
- Roper Technologies
Acquired Phase 3 FGF21 program for MASH fibrosis and cirrhosis.
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inventiva (ADR) | $4.71 | 0.00% | $244.6M | — | — | 210.8 | — |
| Madrigal Pharmaceuticals | $533.76 | −0.02% | $12.33B | — | — | 9.6 | +71.2% |
| Novo Nordisk (ADR) | $45.60 | +0.00% | $202.54B | 11.2 | 18.4 | 4.0 | +0.0% |
| GSK (ADR) | $50.57 | −0.51% | $101.82B | 15.8 | 9.2 | 2.2 | +2.7% |
| Roper Technologies | $425.13 | −0.26% | $43.01B | 17.8 | 18.1 | 5.2 | +8.5% |
| Median | 15.8 | 18.1 | 4.6 | +5.6% |